Hexamerization: Explaining the original sin of IgG-mediated complement activation in acute lung injury

Hrishikesh S. Kulkarni
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/oa_4/3911

This Open Access Publication is brought to you for free and open access by the Open Access Publications at Digital Commons@Becker. It has been accepted for inclusion in 2020-Current year OA Pubs by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Hexamerization: explaining the original sin of IgG-mediated complement activation in acute lung injury

Hrishikesh S. Kulkarni

*J Clin Invest.* 2024;134(11):e181137. [https://doi.org/10.1172/JCI181137](https://doi.org/10.1172/JCI181137).

**Commentary**

Although antibody-mediated lung damage is a major factor in transfusion-related acute lung injury (ALI), autoimmune lung disease (for example, coatomer subunit α [COPA] syndrome), and primary graft dysfunction following lung transplantation, the mechanism by which antigen-antibody complexes activate complement to induce lung damage remains unclear. In this issue of the *JCI*, Cleary and colleagues utilized several approaches to demonstrate that IgG forms hexamers with MHC class I alloantibodies. This hexamerization served as a key pathophysiological mechanism in alloimmune lung injury models and was mediated through the classical pathway of complement activation. Additionally, the authors provided avenues for exploring therapeutics for this currently hard-to-treat clinical entity that has several etiologies but a potentially focused mechanism.

Find the latest version:

[https://jci.me/181137/pdf](https://jci.me/181137/pdf)
Hexamerization: explaining the original sin of IgG-mediated complement activation in acute lung injury

Hrishikesh S. Kulkarni
Division of Pulmonary and Critical Care Medicine, John T. Milliken Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

Although antibody-mediated lung damage is a major factor in transfusion-related acute lung injury (ALI), autoimmune lung disease (for example, coatomer subunit α [COPA] syndrome), and primary graft dysfunction following lung transplantation, the mechanism by which antigen-antibody complexes activate complement to induce lung damage remains unclear. In this issue of the JCI, Cleary and colleagues utilized several approaches to demonstrate that IgG forms hexamers with MHC class I alloantibodies. This hexamerization served as a key pathophysiological mechanism in alloimmune lung injury models and was mediated through the classical pathway of complement activation. Additionally, the authors provided avenues for exploring therapeutics for this currently hard-to-treat clinical entity that has several etiologies but a potentially focused mechanism.

Antibody-mediated lung damage
Surface-bound antigen-antibody complexes can initiate the proteolytic cascade of complement by binding to and activating the C1 complex, which is known as the classical pathway of complement activation (1). Antibody-dependent complement activation requires binding of one Fab arm to the target with the other remaining free, thereby allowing the formation of IgG hexameric Fc platforms (2). IgG subclass members IgG1 and IgG3 and IgM are known to activate complement via C1q binding to their Fc region (3). IgA lacks a site for C1q binding but is still able to activate the complement cascade via the mannose-binding lectin pathway (4). Binding of C1q to a surface results in the activation and assembly of two copies each of the serine proteases C1r and C1s (5), which can cleave C4 to C4b (and C4a), and C2 to C2b (and C2a), thus forming the C3 convertase (C4bC2b, formerly referred to as C4bC2a) (6). The C3 convertase cleaves C3, which generates C3a, an anaphylatoxin that is also a potent inflammatory mediator (7). Importantly, addition of a C3b to the C3 convertase forms the C5 convertase, leading to a membrane attack complex (MAC) that can perturb membranes and result in cell lysis (Figure 1) (8).

Although antibody-mediated lung damage is a major contributing factor in transfusion-related acute lung injury (TRALI) (9), autoimmune lung disease (for example, coatomer subunit α [COPA] syndrome) (10), as well as primary graft dysfunction (PGD) occurring after lung transplantation (11), the mechanism by which antigen-antibody complexes activate the complement system to induce lung damage remains unclear. A theory that has increasingly gained traction involves the formation of IgG hexamers from IgG1 and IgG3 antibodies on antigenic surfaces by Fc-domain interactions that result in complement activation and increased deposition on these target surfaces (2, 12). Whether this hexamer assembly explains alloantibody-mediated lung damage in vivo has been an unanswered question in the field.

Antibody hexamerization in complement-mediated alloimmune acute lung injury
In this issue of the JCI, Cleary et al. utilized several approaches to demonstrate that IgG forms hexamers with MHC-I Class I alloantibodies, and this hexamerization is required for complement-mediated alloimmune acute lung injury (ALI) (13). They used multiple orthogonal approaches to block hexamerization, such as antibody carbamylation, the knockin mutation K439E in the Fc region, and a treatment with domain B from Staphylococcal protein A, all of which reduced alloantibody-mediated ALI. Conversely, mutations in the Fc region that promoted hexamerization worsened this phenotype. Utilizing C1q-deficient mice, the authors demonstrated a key role of the classical pathway of complement in the pathophysiology of their model. Additionally, they pinpointed the specific location of antibody-mediated complement deposition, specifically on the pulmonary endothelium. Finally, in an elegant lung injury model involving the administration of 34-1-2S, a monoclonal antibody that preferentially binds MHC class I antigens, the authors demonstrated a causal relationship between IgG hexamerization and lung damage. They administered 34-1-2S to transgenic mice expressing human FCGR2A, and then used a recombinant Fc hexamer “decoy” therapeutic. This study, therefore, convincingly demonstrates that IgG hexamerization is required for alloantibody-mediated ALI. Additionally, the study provides unique therapeutic avenues for an otherwise hard-to-treat critical illness, the current treatment of which is primarily supportive. Thus, the study by Cleary et al. (13) not only provides a unique opportuni-

Related Article: https://doi.org/10.1172/JCI178351

Conflict of Interest: The author has declared that no conflict of interest exists.
Copyright: © 2024, Kulkarni et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
to reflect on our current understanding of alloantibody-mediated lung injury, but also generates key questions as to how we may be able to design subsequent studies to translate therapeutics from preclinical models of complement-dependent alloimmune lung injury to patient care.

The time course of complement activation in alloimmune ALI
Given that IgG hexamerization induces alloantibody-mediated lung damage via activation of the classical pathway of complement, understanding the time course for initiation of complement activation and injury is important in this disease. The pathophysiology of the ALI model used by Cleary et al. has two major components — an early component, occurring within minutes, related to intravascular platelet and neutrophil responses that can limit lung microvascular perfusion, and a following, later component involving inflammatory injury of the endothelium that increases lung vascular permeability (13). The authors have previously shown that complement activation, as demonstrated by C3 deposition, occurs within five minutes of the inciting event, with complement-dependent intravascular platelet and neutrophil responses observed within five to ten minutes of 34-1-2S injection (14). The work by Cleary et al. advances our understanding of the pathophysiology of alloantibody-mediated damage, in that pulmonary edema was detectable around 15 minutes after 34-1-2S injection, which follows the onset of intravascular platelet and neutrophil responses observed within five to ten minutes of 34-1-2S injection (13). Classical complement activation continued for several hours after the inciting event, and its footprint remained even after the vascular permeability had resolved (e.g., at 24 hours) (13), which is consistent with the hallmarks of a different disease, C4d-positive, antibody-mediated rejection (AMR) following lung transplantation (15). Yet, susceptible hosts (in this case, hFCGR2A-transgenic mice) became more hypoxic than did their littermates in the setting of alloantibody-mediated damage and often died before pulmonary edema developed, suggesting that limiting microvascular lung perfusion is a key component of this model. Moreover, these susceptible hosts often had increased leukocyte recruitment into their lungs, and thus the survivors may have developed worse pulmonary edema (13).

Therefore, this model of alloimmune lung damage — occurring within minutes to hours of an 34-1-2S injection — creates an opportunity to investigate not only when complement activation occurs, but also when it terminates. The determining factors of its termination (for example, regulatory proteins), its interplay with neutrophil recruitment and alveolar-capillary barrier disruption, and how complement ties into the resolution of alloimmune lung injury are questions requiring further
attention. Addressing these questions may help determine the optimal timing and target for therapies. For example, would it be better to target canonical proteins such as C1q or C5 in alloimmune lung injury, as has previously been done in AMR (16, 17)? And until when would this approach be effective, compared with using a strategy that interferes with antibody binding (for example, intravenous Ig [IVIg] therapy) in combination with plasmapheresis to clear out preexisting antibodies until antibody-depleting therapies kick in (18)? Alternatively, should we work toward upregulating or delivering complement regulatory proteins locally to accelerate the termination of complement activation (19, 20)? Finally, given that neutrophil recruitment was increased in this model (13), neutrophil degranulation and neutrophil extracellular trap–mediated (NET-mediated) damage is a feature of TRALI (21), and C5aR1 signaling via complement cascade activation drives lung injury through NETs (22), this study, along with others, creates a precedent to interrogate whether complement modulation would affect factors inciting alloimmune ALI.

Interfering with alloimmune ALI

Another important contribution of Cleary et al. are the methods by which hexamerization were inhibited to abrogate complement-mediated alloimmune ALI. There are several caveats that need to be considered as such therapeutics emerge from preclinical models into the clinical arena. First, the authors appropriately used multiple doses of human IgG1-34-1-2S to develop a model of sublethal ALI in susceptible mice. Subsequently, they randomized mice to receive CSL777, SCIg, or vehicle controls prior to injection with 34-1-2S. CSL777 is an investigational recombinant Fc hexamer serving as a “decoy” treatment that inhibits classical complement activation. It was based on a structure, known as entry 7X13, in the experimental Protein Data Bank (23). SCIg is a human plasma–derived immunoglobulin product that is currently used to treat antibody-mediated diseases. This approach allowed the authors to test how pulmonary complement deposition, and thus activation, was affected in their model. CSL777 resulted in considerably lower pulmonary endotheli-


